Background Patients who develop relapsing-remitting multiple sclerosis (MS) present with a
first clinical demyelinating event. In this double-blind, multicentre, randomised, phase 3 …

BackgroundThis study aimed to determine whether patients with post-traumatic stress
disorder (PTSD) show difficulty in recruitment of the regions of the frontal and parietal cortex …

Enhanced brain reward function could contribute to resilience to trauma. Reward circuitry in
active duty, resilient special forces (SF) soldiers was evaluated using functional magnetic …

The safety, tolerability, pharmacokinetics, and pharmacodynamics of PF‐06700841 were
assessed in a randomized, double‐blind, placebo‐controlled, single‐ and multiple‐dose …

BackgroundFrom a cognitive neuroscience perspective, the emotional attentional bias in
post-traumatic stress disorder (PTSD) could be conceptualized either as emotional hyper-…

BACKGROUND AND PURPOSE: Slowly expanding/evolving lesions measured by conventional
T1-weighted/T2-weighted brain MR imaging may contribute to progressive disability …

The IL-23/T helper type 17 cell axis is a target for psoriasis. The TYK2/Janus kinase 1 inhibitor
PF-06700841 will directly suppress TYK2-dependent IL-12 and IL-23 signaling and Janus …

Introduction: Multiple sclerosis (MS) is a chronic immune-mediated disorder of the central
nervous system leading to progressive neurodegeneration and disability. Until 2010, all …

… Mr Scaramozza reported being an employee and shareholder of Biogen outside the
submitted work. Dr Alroughani reported receiving personal fees from Biogen, Novartis, Sanofi, …

Background Blockade of tyrosine kinase 2 (TYK2) signalling has previously shown therapeutic
potential in the treatment of psoriasis. The primary objective of this study was to assess …